Navigation Links
InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
Date:9/17/2009

R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as RG7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

About National Jewish Health

National Jewish Health is known worldwide for treatment of patients with respiratory, immune and related disorders, and for groundbreaking medical research. Founded in 1899 as a nonprofit hospital, National Jewish Health provides the best integrated and innovative care for patients and their families; seeks to understand and find cures for the diseases we research; and educates and trains the next generation of healthcare professionals to be leaders in medicine and science. We pursue this vision by pioneering individualized medicine programs which embrace the paradigm shift from reactive medicine to proactive, personalized healthcare. For 11 consecutive years, U.S. News & World Report has ranked National Jewish Health the No. 1 respiratory hospital in the nation. Scholarly publisher Thomson Scientific has ranked National Jewish among the 25 most influential research institutions in the world in its areas of focus. Further information can be found by visiting www.nationaljewish.org.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... Feb. 26, 2015 On behalf of biotech ... companies, Wilentz, Goldman & Spitzer, P.A. (Wilentz) ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... denying motions for judgment notwithstanding the verdict, a new ...
(Date:2/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... fiscal first quarter ended December  31, 2014. All figures ... unless otherwise stated. "During the quarter ... existing customers and add to our sales pipeline," said ...
(Date:2/26/2015)... LA JOLLA, Calif. , Feb. 26, 2015 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and development ... Kleanthis G. Xanthopoulos , Ph.D., President and Chief Executive ... the Cowen and Company 35 th Annual Healthcare ... EST.  The conference is being held at the Boston ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... Staff; San Diego Office to Offer Regulatory ... Operations ... a,leader in providing software and services to streamline the drug,development lifecycle, ... a new facility in San Diego. The announcements,illustrate the company,s newly ...
... 58th Annual Meeting of the American ... TAMPA, Fla., Aug. 15 Romark Laboratories announced that,it ... (nitazoxanide) for,treating chronic hepatitis C in the United States. ... effectiveness and safety,of Alinia tablets administered in combination with ...
... Aug. 15 Barr,Pharmaceuticals, Inc. (NYSE: BRL ... has initiated a challenge of the patent listed ... Chilcott,s Femcon(R),FE (norethindrone and ethinyl estradiol) chewable oral ... to file an Abbreviated New Drug,Application (ANDA) containing ...
Cached Biology Technology:ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 2ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 3ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 4Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 2Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 3Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 4Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 3
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... include risk for heart attacks and strokes in addition ... MJ called delta-9-tetrahyrdocannabinol (THC) is believed to exert these ... several cell types in various organs. Scientists have ... heart, liver, kidney, and spleen. In this study, ...
... in social groups, and that includes humans, blindly following a ... this, animals have developed simple but effective behaviour to follow ... rather than follow a single group member. This ... of an individual as the group recognise that consensus is ...
... have an ambivalent relationship with light. They need it to ... of high-energy chemical intermediates that can injure or kill the ... conversion of sunlight into chemical energy cannot keep up with ... have anywhere to go because the system is jammed up ...
Cached Biology News:When following the leader can lead into the jaws of death 2When following the leader can lead into the jaws of death 3ASU researchers synthesize molecule with self-control 2
WTAP Antibody...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Biology Products: